Sequana Announces Results of alfapump® Multicentre, Post-Marketing Surveillance Registry

Sequana Medical Announces Publication of Results of alfapump(R) Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology and Therapeutics (AP+T).

Zurich, SWITZERLAND 4 October 2017 -- Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of “Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis”, the results of the first 56 patients in the alfapump® multicentre Post-Marketing Surveillance Registry (PMSR) in AP&T (Alimentary Pharmacology & Therapeutics) (http://onlinelibrary.wiley.com/doi/10.1111/apt.14331/epdf).

View full press release

Download full press release here